| pubmed-article:8477204 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8477204 | lifeskim:mentions | umls-concept:C0194037 | lld:lifeskim |
| pubmed-article:8477204 | lifeskim:mentions | umls-concept:C0019829 | lld:lifeskim |
| pubmed-article:8477204 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:8477204 | pubmed:dateCreated | 1993-5-25 | lld:pubmed |
| pubmed-article:8477204 | pubmed:abstractText | The use of high-dose cyclophosphamide, carmustine, and etoposide (CBV) with autologous bone marrow transplantation (ABMT) results in long-term disease-free survival of about 30% in patients with relapsed Hodgkin's disease. Laboratory and clinical data show that cisplatin is synergistic with etoposide and carmustine, with non-overlapping extramedullary toxicity. Twenty-one patients with relapsed Hodgkin's disease that had progressed after both MOPP-like and ABVD-like regimens were treated with CBV plus cisplatin (90 mg/m2) and ABMT. The CR rate was 55%; the three-year disease-free and overall survival were 29% and 38% respectively; these results are comparable to prior experience with CBV. Performance status was strongly correlated with achievement of CR, survival, and time to treatment failure. Nephrotoxicity was seen in 3 patients, and ototoxicity in 1 patient. Although cisplatin could be added to CBV with minimal additional toxicity, the results obtained in this small patient population were not better than those of the earlier regimen. A larger trial in patients not previously exposed to cisplatin may better define the role of its addition to CBV. | lld:pubmed |
| pubmed-article:8477204 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8477204 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8477204 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8477204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8477204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8477204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8477204 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8477204 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8477204 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:8477204 | pubmed:author | pubmed-author:DickeK AKA | lld:pubmed |
| pubmed-article:8477204 | pubmed:author | pubmed-author:SpitzerGG | lld:pubmed |
| pubmed-article:8477204 | pubmed:author | pubmed-author:CabanillasFF | lld:pubmed |
| pubmed-article:8477204 | pubmed:author | pubmed-author:JagannathSS | lld:pubmed |
| pubmed-article:8477204 | pubmed:author | pubmed-author:HorwitzL JLJ | lld:pubmed |
| pubmed-article:8477204 | pubmed:author | pubmed-author:HagemeisterFF | lld:pubmed |
| pubmed-article:8477204 | pubmed:author | pubmed-author:SpinoloJ AJA | lld:pubmed |
| pubmed-article:8477204 | pubmed:author | pubmed-author:VelásquezWW | lld:pubmed |
| pubmed-article:8477204 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8477204 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:8477204 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8477204 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8477204 | pubmed:pagination | 71-7 | lld:pubmed |
| pubmed-article:8477204 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:meshHeading | pubmed-meshheading:8477204-... | lld:pubmed |
| pubmed-article:8477204 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8477204 | pubmed:articleTitle | Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. | lld:pubmed |
| pubmed-article:8477204 | pubmed:affiliation | University of Texas M. D. Anderson Cancer Center, Houston. | lld:pubmed |
| pubmed-article:8477204 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8477204 | pubmed:publicationType | Clinical Trial | lld:pubmed |
